Silver Book Fact

Adjusted-dose warfarin reduced stroke risk in AFib patients

Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation
patients by 60%. Antiplatelet agents reduced risk by 20%.

Hart, RG, LA Pearce, and MI Aguilar. Meta-Analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007; 146(12): 857-67. http://www.annals.org/content/146/12/857.full

Reference

Title
Meta-Analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
Publication
Ann Intern Med
Publication Date
2007
Authors
Hart, RG, LA Pearce, and MI Aguilar
Volume & Issue
Volume 146, Issue 12
Pages
857-67
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.